SCHEMBL9963409

SCHEMBL9963409

CC(C)N1CCN(Cc2n[nH]c3ccccc23)[C@@H](C)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 6/20 0.38
KDM4E B2RXH2 6/20 0.37
RAB9A P51151 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 3/20 0.36
HPGD P15428 3/20 0.36
NPC1 O15118 2/20 0.36
TP53 P04637 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DRD4 P21917 2/20 0.35
PARP1 P09874 1/20 0.34
ACHE P22303 1/20 0.33
ALPL P05186 1/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9965976 0.84 FGFR1 (0.41) KDM4ERAB9AALDH1A1HSD17B10HPGD
SCHEMBL20008970 0.81 PARP1 (0.42) KDM4EALDH1A1KMT2AMEN1GAA
SCHEMBL9934884 0.77 KDM4E (0.38) KDM4ERAB9AALDH1A1HSD17B10HPGD
SCHEMBL19967980 0.74 SLC6A9 (0.49) SLC6A9KDM4EKMT2AMEN1MAPT
SCHEMBL9963401 0.71 LMNA (0.45) SLC6A9KDM4EALDH1A1KMT2ADRD4
SCHEMBL9963404 0.71 LMNA (0.45) SLC6A9KDM4EALDH1A1KMT2ADRD4
SCHEMBL8635072 0.70 MAPK1 (0.52) KDM4ERAB9AALDH1A1HSD17B10HPGD
SCHEMBL28308987 0.68 HRH3 (0.48) SLC6A9DRD4
SCHEMBL20012646 0.68 KMT2A (0.45) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL18080912 0.68 HTR6 (0.56) KDM4EGAAPARP1ACHEMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 SLC6A9 3427/4885KDM4E 3804/4885RAB9A 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.